These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 33390978)

  • 1. Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study.
    Wang T; McAuslane N; Liberti L; Gardarsdottir H; Goettsch W; Leufkens H
    Front Pharmacol; 2020; 11():594549. PubMed ID: 33390978
    [No Abstract]   [Full Text] [Related]  

  • 2. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
    Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
    J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
    Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
    Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile.
    Wang T; McAuslane N; Goettsch WG; Leufkens HGM; De Bruin ML
    Front Pharmacol; 2022; 13():948161. PubMed ID: 35924050
    [No Abstract]   [Full Text] [Related]  

  • 5. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
    Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
    Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value added medicines: what value repurposed medicines might bring to society?
    Toumi M; Rémuzat C
    J Mark Access Health Policy; 2017; 5(1):1264717. PubMed ID: 28265347
    [No Abstract]   [Full Text] [Related]  

  • 8. Early dialogue with health technology assessment bodies: a European perspective.
    Cuche M; Beckerman R; Chowdhury CA; van Weelden MA
    Int J Technol Assess Health Care; 2014 Dec; 30(6):571-8. PubMed ID: 25816822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions.
    Wang T; McAuslane N; Liberti L; Leufkens H; Hövels A
    Value Health; 2018 Jun; 21(6):707-714. PubMed ID: 29909876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement.
    Wang T; McAuslane N; Goettsch WG; Leufkens HGM; De Bruin ML
    Int J Technol Assess Health Care; 2023 Apr; 39(1):e20. PubMed ID: 37039100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations.
    Vreman RA; Mantel-Teeuwisse AK; Hövels AM; Leufkens HGM; Goettsch WG
    Value Health; 2020 Jan; 23(1):10-16. PubMed ID: 31952664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of health technology assessment bodies in shaping drug development.
    Ciani O; Jommi C
    Drug Des Devel Ther; 2014; 8():2273-81. PubMed ID: 25419117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HTA decision-making for drugs for rare diseases: comparison of processes across countries.
    Stafinski T; Glennie J; Young A; Menon D
    Orphanet J Rare Dis; 2022 Jul; 17(1):258. PubMed ID: 35804398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing access to orphan medicinal products in Europe.
    Zamora B; Maignen F; O'Neill P; Mestre-Ferrandiz J; Garau M
    Orphanet J Rare Dis; 2019 May; 14(1):95. PubMed ID: 31053154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical companies' views on a health technology assessment (HTA) entity in Saudi Arabia.
    Al-Omar HA; Attuwaijri AA; Aljuffali IA
    Saudi Pharm J; 2020 Jun; 28(6):662-668. PubMed ID: 32550796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timely, consistent, transparent assessment of market access evidence: implementing tools based on the HTA Core Model® in a pharmaceutical company.
    Ducournau P; Irl C; Tatt I; McCarvil M; Gyldmark M
    Int J Technol Assess Health Care; 2019 Jan; 35(1):10-16. PubMed ID: 30789111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans.
    Salek S; Lussier Hoskyn S; Johns JR; Allen N; Sehgal C
    Front Pharmacol; 2019; 10():196. PubMed ID: 30983993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Acceptance of Indirect Treatment Comparison Methods in Oncology by Health Technology Assessment Agencies in England, France, Germany, Italy, and Spain.
    Macabeo B; Rotrou T; Millier A; François C; Laramée P
    Pharmacoecon Open; 2024 Jan; 8(1):5-18. PubMed ID: 38097828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient advocacy group involvement in health technology assessments: an observational study.
    Single A; Cabrera A; Fifer S; Tsai J; Paik JY; Hope P
    Res Involv Engagem; 2021 Nov; 7(1):83. PubMed ID: 34823610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.